Literature DB >> 30552009

Structural and computational basis for potent inhibition of glutamate carboxypeptidase II by carbamate-based inhibitors.

Cyril Barinka1, Zora Novakova2, Niyada Hin3, Daniel Bím4, Dana V Ferraris5, Bridget Duvall3, Gabriel Kabarriti3, Reiji Tsukamoto3, Milos Budesinsky4, Lucia Motlova2, Camilo Rojas6, Barbara S Slusher7, Tibor András Rokob8, Lubomír Rulíšek9, Takashi Tsukamoto10.   

Abstract

A series of carbamate-based inhibitors of glutamate carboxypeptidase II (GCPII) were designed and synthesized using ZJ-43, N-[[[(1S)-1-carboxy-3-methylbutyl]amino]carbonyl]-l-glutamic acid, as a molecular template in order to better understand the impact of replacing one of the two nitrogen atoms in the urea-based GCPII inhibitor with an oxygen atom. Compound 7 containing a C-terminal 2-oxypentanedioic acid was more potent than compound 5 containing a C-terminal glutamic acid (2-aminopentanedioic acid) despite GCPII's preference for peptides containing an N-terminal glutamate as substrates. Subsequent crystallographic analysis revealed that ZJ-43 and its two carbamate analogs 5 and 7 with the same (S,S)-stereochemical configuration adopt a nearly identical binding mode while (R,S)-carbamate analog 8 containing a d-leucine forms a less extensive hydrogen bonding network. QM and QM/MM calculations have identified no specific interactions in the GCPII active site that would distinguish ZJ-43 from compounds 5 and 7 and attributed the higher potency of ZJ-43 and compound 7 to the free energy changes associated with the transfer of the ligand from bulk solvent to the protein active site as a result of the lower ligand strain energy and solvation/desolvation energy. Our findings underscore a broader range of factors that need to be taken into account in predicting ligand-protein binding affinity. These insights should be of particular importance in future efforts to design and develop GCPII inhibitors for optimal inhibitory potency.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Crystal structure; Glutamate carboxypeptidase II; Metallopeptidase; Prostate-specific membrane antigen

Mesh:

Substances:

Year:  2018        PMID: 30552009      PMCID: PMC6374116          DOI: 10.1016/j.bmc.2018.11.022

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.461


  35 in total

1.  Total synthesis and anti-tubulin activity of epi-c3 analogues of cryptophycin-24.

Authors:  Suzanne B Buck; Jacquelyn K Huff; Richard H Himes; Gunda I Georg
Journal:  J Med Chem       Date:  2004-07-01       Impact factor: 7.446

2.  Climbing the density functional ladder: nonempirical meta-generalized gradient approximation designed for molecules and solids.

Authors:  Jianmin Tao; John P Perdew; Viktor N Staroverov; Gustavo E Scuseria
Journal:  Phys Rev Lett       Date:  2003-09-30       Impact factor: 9.161

Review 3.  NAAG peptidase inhibitors and their potential for diagnosis and therapy.

Authors:  Jia Zhou; Joseph H Neale; Martin G Pomper; Alan P Kozikowski
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

Review 4.  Chemical applications carried out by local pair natural orbital based coupled-cluster methods.

Authors:  Manuel Sparta; Frank Neese
Journal:  Chem Soc Rev       Date:  2014-03-27       Impact factor: 54.564

5.  Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities.

Authors:  Michal Navrátil; Jan Tykvart; Jiří Schimer; Petr Pachl; Václav Navrátil; Tibor András Rokob; Klára Hlouchová; Lubomír Rulíšek; Jan Konvalinka
Journal:  FEBS J       Date:  2016-06-06       Impact factor: 5.542

6.  N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer.

Authors:  Ronnie C Mease; Crystal L Dusich; Catherine A Foss; Hayden T Ravert; Robert F Dannals; Jurgen Seidel; Andrew Prideaux; James J Fox; George Sgouros; Alan P Kozikowski; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

7.  Structural insight into the evolutionary and pharmacologic homology of glutamate carboxypeptidases II and III.

Authors:  Klara Hlouchova; Cyril Barinka; Jan Konvalinka; Jacek Lubkowski
Journal:  FEBS J       Date:  2009-08       Impact factor: 5.542

8.  Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.

Authors:  Alan P Kozikowski; Jiazhong Zhang; Fajun Nan; Pavel A Petukhov; Ewa Grajkowska; Jarda T Wroblewski; Tatsuo Yamamoto; Tomasz Bzdega; Barbara Wroblewska; Joseph H Neale
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

9.  REFMAC5 for the refinement of macromolecular crystal structures.

Authors:  Garib N Murshudov; Pavol Skubák; Andrey A Lebedev; Navraj S Pannu; Roberto A Steiner; Robert A Nicholls; Martyn D Winn; Fei Long; Alexei A Vagin
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18

10.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21
View more
  4 in total

1.  Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?

Authors:  Veronika Barbara Felber; Manuel Amando Valentin; Hans-Jürgen Wester
Journal:  EJNMMI Radiopharm Chem       Date:  2021-02-26

Review 2.  Mechanisms of Proteolytic Enzymes and Their Inhibition in QM/MM Studies.

Authors:  Brigitta Elsässer; Peter Goettig
Journal:  Int J Mol Sci       Date:  2021-03-22       Impact factor: 5.923

3.  Interactions of Urea-Based Inhibitors with Prostate-Specific Membrane Antigen for Boron Neutron Capture Therapy.

Authors:  Qiaoyu Hu; Kevin Padron; Daiki Hara; Junwei Shi; Alan Pollack; Rajeev Prabhakar; Wensi Tao
Journal:  ACS Omega       Date:  2021-12-01

4.  Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.

Authors:  Martin K Bakht; John J Hayward; Farsheed Shahbazi-Raz; Magdalena Skubal; Ryo Tamura; Keith F Stringer; Daniel Meister; Varadha Balaji Venkadakrishnan; Hui Xue; Adam Pillon; Mathew Stover; Adam Tronchin; Bre-Anne Fifield; Lavleen Mader; Sheng-Yu Ku; Gi Jeong Cheon; Keon Wook Kang; Yuzhuo Wang; Xuesen Dong; Himisha Beltran; Jan Grimm; Lisa A Porter; John F Trant
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-25       Impact factor: 12.779

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.